Mutant p53 as a Therapeutic Target: The Report of Its Death Was an Exaggeration.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Tumor Suppressor Protein p53*/genetics ; Tumor Suppressor Protein p53*/metabolism ; Tumor Suppressor Protein p53*/antagonists & inhibitors ; Neoplasms*/genetics ; Neoplasms*/drug therapy ; Neoplasms*/metabolism ; Neoplasms*/therapy ; Mutation*; Humans ; Animals ; Mice ; Molecular Targeted Therapy

TP53 is the most frequently mutated gene in human cancers. Many studies have reported oncogenic gain of function by mutant p53 and suggested that mutant p53 is a potential therapeutic target. In striking contrast, a recent approach relying on CRISPR-mediated mutagenesis led to the conclusion that mutant p53 removal in tumors had no therapeutic value. However, experimental limitations likely affected this study, including the difficulty of recapitulating the events leading to mutant p53 gain of function in cancer cell lines. Furthermore, a low statistical power may have masked the impact of mutant p53 removal in organoid-derived tumors. Independently, two studies focusing on the human hotspot mutant TP53^Y220C and its murine homolog Trp53^Y217C recently provided compelling evidence that mutant p53 can be a valid therapeutic target. Drugs designed to stabilize the mutant protein and restore wild-type p53 functions, or to inhibit the inflammatory effects associated with mutant p53, appear particularly promising.

Science. 1990 Nov 30;250(4985):1233-8. (PMID: 1978757)
Cancer Res Commun. 2021 Dec;1(3):148-163. (PMID: 34957471)
Cell Death Differ. 2018 Jan;25(1):161-168. (PMID: 29099488)
Cold Spring Harb Perspect Med. 2016 Nov 1;6(11):. (PMID: 27503997)
Eur J Immunol. 2023 Sep;53(9):e2250211. (PMID: 37377275)
Genes Dev. 2018 Nov 1;32(21-22):1420-1429. (PMID: 30366906)
Cancer Discov. 2025 Jun 3;15(6):1159-1179. (PMID: 39945593)
Nature. 2019 Mar;567(7746):105-108. (PMID: 30787433)
Science. 2019 Aug 9;365(6453):599-604. (PMID: 31395785)
Nat Cell Biol. 2009 Aug;11(8):973-9. (PMID: 19597488)
Cancer Discov. 2024 Feb 8;14(2):211-213. (PMID: 38327191)
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15056-61. (PMID: 17015838)
Trends Cell Biol. 2025 Feb;35(2):105-114. (PMID: 39079798)
Genes Dev. 2020 Sep 1;34(17-18):1128-1146. (PMID: 32873579)
J Neurosci Res. 2004 Feb 15;75(4):554-64. (PMID: 14743439)
Sci Rep. 2014 Feb 27;4:4223. (PMID: 24573247)
Leuk Lymphoma. 2024 Oct;65(10):1511-1515. (PMID: 38856690)
Elife. 2025 Apr 14;13:. (PMID: 40223808)
Oncogene. 2007 Apr 2;26(15):2185-90. (PMID: 17401427)
Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a000935. (PMID: 20679336)
Nat Commun. 2024 Jan 2;15(1):180. (PMID: 38167338)
Nat Genet. 1993 May;4(1):42-6. (PMID: 8099841)
Cell Death Differ. 2024 Feb;31(2):133-135. (PMID: 38151545)
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):. (PMID: 27836911)
Science. 1991 Jul 5;253(5015):49-53. (PMID: 1905840)
J Endocrinol. 2024 Apr 29;261(3):. (PMID: 38579776)
PLoS One. 2013 Dec 06;8(12):e82713. (PMID: 24324824)
Cancer Discov. 2025 Jun 3;15(6):1099-1104. (PMID: 40287981)
Trends Cell Biol. 2025 Mar;35(3):258-268. (PMID: 38960851)
Int J Mol Sci. 2020 May 13;21(10):. (PMID: 32414156)
J Endocr Soc. 2018 Oct 22;3(1):91-107. (PMID: 30582096)
Nature. 2023 May;617(7960):386-394. (PMID: 37100912)
Nat Genet. 2025 Jan;57(1):140-153. (PMID: 39774325)
Cancer Discov. 2024 Feb 8;14(2):362-379. (PMID: 37877779)
Science. 2018 Feb 23;359(6378):920-926. (PMID: 29472484)

Keywords: cancer; gain of function; inflammation; p53

0 (Tumor Suppressor Protein p53)
0 (TP53 protein, human)

Date Created: 20250712 Date Completed: 20250712 Latest Revision: 20250717

20260130

PMC12249608

10.3390/ijms26136446

40650221